• Home
  • Documentation
en
Scientific article
Open access
English

Patented drug extension strategies on healthcare spending: a cost-evaluation analysis

ContributorsVernaz, Nathalie; Haller, Guy Serge Antoine; Girardin, François; Huttner, Benediktorcid; Combescure, Christopheorcid; Dayer, Pierre; Muscionico, Daniel; Salomon, Jean-Luc; Bonnabry, Pascal
Published inPLoS medicine, vol. 10, no. 6, e1001460
Publication date2013
Abstract

Drug manufacturers have developed "evergreening" strategies to compete with generic medication after patent termination. These include marketing of slightly modified follow-on drugs. We aimed to estimate the financial impact of these drugs on overall healthcare costs and also to examine the impact of listing these drugs in hospital restrictive drug formularies (RDFs) on the healthcare system as a whole ("spillover effect").

Keywords
  • Cetirizine/economics
  • Costs and Cost Analysis
  • Esomeprazole/economics
  • Female
  • Formularies, Hospital
  • Health Care Costs
  • Humans
  • Male
  • Marketing/economics
  • Middle Aged
  • Nonprescription Drugs/economics
  • Patents as Topic
  • Prescription Drugs/economics
  • Residence Characteristics
  • Time Factors
Affiliation
Research group
Citation (ISO format)
VERNAZ, Nathalie et al. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis. In: PLoS medicine, 2013, vol. 10, n° 6, p. e1001460. doi: 10.1371/journal.pmed.1001460
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal1549-1277
665views
310downloads

Technical informations

Creation04/16/2014 4:36:00 PM
First validation04/16/2014 4:36:00 PM
Update time03/14/2023 9:10:36 PM
Status update03/14/2023 9:10:36 PM
Last indexation05/02/2024 3:07:39 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack